NASDAQ:ARTL

Artelo Biosciences (ARTL) Stock Price, News & Analysis

Artelo Biosciences logo
$1.50 +0.01 (+0.33%)
As of 10:13 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Artelo Biosciences Stock (NASDAQ:ARTL)

Advanced

Key Stats

Today's Range
$1.45
▼
$1.54
50-Day Range
$1.50
▼
$7.31
52-Week Range
$1.43
▼
$179.19
Volume
5,988 shs
Average Volume
282,487 shs
Market Capitalization
$824.74 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company developing treatments that target the endocannabinoid system and related biological pathways. Its research focuses on potential therapies for conditions with significant unmet medical needs, including cancer-related symptoms and pain.

The company’s programs have included ART27.13, a cannabinoid receptor agonist being studied for cancer-related anorexia and cachexia, and ART26.12, a small-molecule inhibitor of fatty acid binding protein 5 under investigation for potential therapeutic applications. Artelo has also developed ART12.11, a cannabidiol-based cocrystal formulation.

Artelo is headquartered in the San Diego area of California. Its work is centered on drug research and development rather than the commercial sale of approved medicines.

AI Generated. May Contain Errors.

Artelo Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
19th Percentile Overall Score

ARTL MarketRank™: 
0.949808533915 of 5 stars

Artelo Biosciences scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Artelo Biosciences has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Artelo Biosciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Artelo Biosciences' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Artelo Biosciences is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Artelo Biosciences is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Artelo Biosciences has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.23% of the float of Artelo Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Artelo Biosciences has a short interest ratio ("days to cover") of 0.72, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Artelo Biosciences has recently decreased by 20.20%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Artelo Biosciences does not currently pay a dividend.

  • Dividend Growth

    Artelo Biosciences does not have a long track record of dividend growth.

  • News Sentiment

    Artelo Biosciences has a news sentiment score of 1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Artelo Biosciences this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    1 people have added Artelo Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Artelo Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    3.20% of the stock of Artelo Biosciences is held by insiders.

  • Percentage Held by Institutions

    0.87% of the stock of Artelo Biosciences is held by institutions.

  • Read more about Artelo Biosciences' insider trading history.
Receive ARTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ARTL Stock News Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
See More Headlines

ARTL Stock Analysis - Frequently Asked Questions

Artelo Biosciences' stock was trading at $32.94 at the beginning of 2026. Since then, ARTL stock has decreased by 95.3% and is now trading at $1.54.

Artelo Biosciences, Inc. (NASDAQ:ARTL) posted its quarterly earnings results on Thursday, November, 12th. The company reported ($3.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($7.02) by $3.83.

Shares of Artelo Biosciences reverse split on the morning of Tuesday, March 10th 2026.The 1-3 reverse split was announced on Friday, March 6th 2026. The number of shares owned by shareholders was adjusted after the market closes on Monday, March 9th 2026. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

Artelo Biosciences (ARTL) raised $80,000 in an initial public offering on Friday, June 21st 2019. The company issued 8,000,000 shares at $0.01 per share.

Shares of ARTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Artelo Biosciences investors own include NIO (NIO), Ford Motor (F), FuelCell Energy (FCEL), Hepion Pharmaceuticals (HEPA), SNDL (SNDL), Tonix Pharmaceuticals (TNXP) and Tesla (TSLA).

Company Calendar

Last Earnings
11/12/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ARTL
CIK
1621221
Fax
N/A
Employees
7
Year Founded
2017

Profitability

EPS (Trailing Twelve Months)
($47.20)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$12.88 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-272.21%
Return on Assets
-159.13%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.47
Quick Ratio
10.47

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$11.39 per share
Price / Book
0.13

Miscellaneous

Outstanding Shares
548,000
Free Float
530,000
Market Cap
$824.74 thousand
Optionable
Not Optionable
Beta
0.01

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:ARTL) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners